Seek truth from facts, competitive symbiosis
Zhengqing Fengtongning shines at the 29th Academic Conference of the Rheumatology Branch of the China Association for Traditional Chinese Medicine, with its clinical value receiving high recognition from authoritative experts.
Category:
Release time:
2025-10-23
From October 16 to 19, 2025, the 29th Academic Conference of the Rheumatology Branch of the China Association for Traditional Chinese Medicine was grandly held in Shenzhen, Guangdong Province. The conference brought together leading experts and scholars from across the country in the field of rheumatology, fostering in-depth discussions on the latest advancements in the diagnosis and treatment of rheumatic diseases, as well as innovative applications of traditional Chinese medicine in clinical practice. Zhengqing Group showcased its core product line, the Zhengqing Fengtongning series, with great success. Through a variety of engaging activities—including academic forums, expert presentations, and interactive booth demonstrations—the company comprehensively highlighted the remarkable efficacy of its products in treating rheumatic and immune-related conditions, earning widespread acclaim from attendees.
During the academic forum session, Liu Wei, Chairman of the Rheumatic Diseases Committee of the Chinese Association of Integrated Traditional and Western Medicine, shared insights on Zhengqing Fengtongning Sustained-Release Tablets. He analyzed the drug's "anti-inflammatory and kidney-protecting" value from the perspective of its mechanism of action, highlighting Zhengqing Fengtongning's selective inhibition of mPGES-1 and elucidating its pivotal role in regulating the prostaglandin E₂ synthesis pathway. This provided robust academic support for both the mechanistic research and clinical applications of the product in treating rheumatic and immune-related diseases.
Experts Li Zhenbin from the Department of Rheumatology and Immunology at Bethune International Peace Hospital, Huang Runyue from Guangdong Provincial Hospital of Traditional Chinese Medicine, and Chen Shixian from Nanfang Hospital of Southern Medical University conducted an in-depth analysis of Zhengqing Fengtongning—from mechanistic studies to clinical data—highlighting its remarkable advantages and clinical significance in treating rheumatic immune diseases such as rheumatoid arthritis, both in terms of its underlying mechanisms and practical applications, thereby providing strong support for the product's scientific use.
To further promote the clinical application and academic exchange of Zhengqing Fengtongning in the field of rheumatology, the conference simultaneously hosted the "Zhengqing Fengtongning 50-Person Forum," inviting experts from top-tier Grade-III hospitals to participate. During the meeting, the product manager systematically introduced Zhengqing Fengtongning's mechanism of action in rheumatology, its clinical research findings, as well as the fee structure for specialized acupuncture techniques, enabling the experts to gain a comprehensive understanding of the product’s academic backing and practical applications. The forum featured a vibrant atmosphere, with experts freely sharing their insights based on their clinical experience. All participants unanimously praised the remarkable efficacy of Zhengqing Fengtongning, emphasizing that it offers a safe and effective treatment option for patients suffering from rheumatic and immune-related diseases.
At the conference exhibition area, Zhengqing Group has also thoughtfully created a distinctive booth, blending "academic insights with engaging elements" to draw in numerous attendees. Several experts visited the booth to engage in in-depth discussions with the Zhengqing team about their clinical experience using Zhengqing Fengtongning, while the venue continued to buzz with an endless stream of visitors.
This time at the conference, Zhengqing Fengtongning has further solidified its professional standing in the field of rheumatology treatment, thanks to its robust scientific research foundation and remarkable clinical efficacy. Moving forward, Zhengqing Group will continue to deeply invest in innovative R&D of traditional Chinese medicine, strengthen academic collaborations with experts nationwide, and strive to bring renewed hope for recovery to more patients suffering from rheumatic and immune-related diseases. Ultimately, this effort will contribute to the high-quality development of TCM in the diagnosis and treatment of rheumatic disorders.
Copyright Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Virtual Showroom：
Agent：
OA：
CRM：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： Hunan Zhengqing Pharmaceutical Group Co., Ltd.
表单验证提示文本： Please enter correct content!
循环体没有内容时： Updating......
CSS / JS 文件放置地